Global Gene Engineered Subunit Vaccine Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Gene Engineered Subunit Vaccine market size was valued at US$ million in 2023. With growing demand in downstream market, the Gene Engineered Subunit Vaccine is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Gene Engineered Subunit Vaccine market. Gene Engineered Subunit Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Gene Engineered Subunit Vaccine. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Gene Engineered Subunit Vaccine market.
A gene engineered subunit vaccine or a bio-recombinant subunit vaccine refers to the expression of a protective antigen gene in a prokaryotic or eukaryotic cell, and a vaccine made from a gene product—protein or polypeptide.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Gene Engineered Subunit Vaccine market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Gene Engineered Subunit Vaccine market. It may include historical data, market segmentation by Type (e.g., Therapeutic Gene Engineered Subunit Vaccine, Preventative Gene Engineered Subunit Vaccine), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Gene Engineered Subunit Vaccine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Gene Engineered Subunit Vaccine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Gene Engineered Subunit Vaccine industry. This include advancements in Gene Engineered Subunit Vaccine technology, Gene Engineered Subunit Vaccine new entrants, Gene Engineered Subunit Vaccine new investment, and other innovations that are shaping the future of Gene Engineered Subunit Vaccine.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Gene Engineered Subunit Vaccine market. It includes factors influencing customer ' purchasing decisions, preferences for Gene Engineered Subunit Vaccine product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Gene Engineered Subunit Vaccine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Gene Engineered Subunit Vaccine market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Gene Engineered Subunit Vaccine market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Gene Engineered Subunit Vaccine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Gene Engineered Subunit Vaccine market.
Market Segmentation:
Gene Engineered Subunit Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Gene Engineered Subunit Vaccine market?
What factors are driving Gene Engineered Subunit Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Gene Engineered Subunit Vaccine market opportunities vary by end market size?
How does Gene Engineered Subunit Vaccine break out type, application?
According to our LPI (LP Information) latest study, the global Gene Engineered Subunit Vaccine market size was valued at US$ million in 2023. With growing demand in downstream market, the Gene Engineered Subunit Vaccine is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Gene Engineered Subunit Vaccine market. Gene Engineered Subunit Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Gene Engineered Subunit Vaccine. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Gene Engineered Subunit Vaccine market.
A gene engineered subunit vaccine or a bio-recombinant subunit vaccine refers to the expression of a protective antigen gene in a prokaryotic or eukaryotic cell, and a vaccine made from a gene product—protein or polypeptide.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Gene Engineered Subunit Vaccine market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Gene Engineered Subunit Vaccine market. It may include historical data, market segmentation by Type (e.g., Therapeutic Gene Engineered Subunit Vaccine, Preventative Gene Engineered Subunit Vaccine), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Gene Engineered Subunit Vaccine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Gene Engineered Subunit Vaccine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Gene Engineered Subunit Vaccine industry. This include advancements in Gene Engineered Subunit Vaccine technology, Gene Engineered Subunit Vaccine new entrants, Gene Engineered Subunit Vaccine new investment, and other innovations that are shaping the future of Gene Engineered Subunit Vaccine.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Gene Engineered Subunit Vaccine market. It includes factors influencing customer ' purchasing decisions, preferences for Gene Engineered Subunit Vaccine product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Gene Engineered Subunit Vaccine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Gene Engineered Subunit Vaccine market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Gene Engineered Subunit Vaccine market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Gene Engineered Subunit Vaccine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Gene Engineered Subunit Vaccine market.
Market Segmentation:
Gene Engineered Subunit Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Therapeutic Gene Engineered Subunit Vaccine
- Preventative Gene Engineered Subunit Vaccine
- Human Use
- Veterinary Use
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck
- GSK
- Tiantan
- Pulike
- Greffex
- CureVac
- Yebio
- Sanofi Pasteur SA
- Virbac
- Pfizer Inc.
- Walvax Biotechnology
- Kontec
- Novavax
- Sanofi Pasteur
- Bharat Biotech
- GlaxoSmithKline
- Pfizer
- Moderna
What is the 10-year outlook for the global Gene Engineered Subunit Vaccine market?
What factors are driving Gene Engineered Subunit Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Gene Engineered Subunit Vaccine market opportunities vary by end market size?
How does Gene Engineered Subunit Vaccine break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Gene Engineered Subunit Vaccine Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Gene Engineered Subunit Vaccine by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Gene Engineered Subunit Vaccine by Country/Region, 2019, 2023 & 2030
2.2 Gene Engineered Subunit Vaccine Segment by Type
2.2.1 Therapeutic Gene Engineered Subunit Vaccine
2.2.2 Preventative Gene Engineered Subunit Vaccine
2.3 Gene Engineered Subunit Vaccine Sales by Type
2.3.1 Global Gene Engineered Subunit Vaccine Sales Market Share by Type (2019-2024)
2.3.2 Global Gene Engineered Subunit Vaccine Revenue and Market Share by Type (2019-2024)
2.3.3 Global Gene Engineered Subunit Vaccine Sale Price by Type (2019-2024)
2.4 Gene Engineered Subunit Vaccine Segment by Application
2.4.1 Human Use
2.4.2 Veterinary Use
2.5 Gene Engineered Subunit Vaccine Sales by Application
2.5.1 Global Gene Engineered Subunit Vaccine Sale Market Share by Application (2019-2024)
2.5.2 Global Gene Engineered Subunit Vaccine Revenue and Market Share by Application (2019-2024)
2.5.3 Global Gene Engineered Subunit Vaccine Sale Price by Application (2019-2024)
3 GLOBAL GENE ENGINEERED SUBUNIT VACCINE BY COMPANY
3.1 Global Gene Engineered Subunit Vaccine Breakdown Data by Company
3.1.1 Global Gene Engineered Subunit Vaccine Annual Sales by Company (2019-2024)
3.1.2 Global Gene Engineered Subunit Vaccine Sales Market Share by Company (2019-2024)
3.2 Global Gene Engineered Subunit Vaccine Annual Revenue by Company (2019-2024)
3.2.1 Global Gene Engineered Subunit Vaccine Revenue by Company (2019-2024)
3.2.2 Global Gene Engineered Subunit Vaccine Revenue Market Share by Company (2019-2024)
3.3 Global Gene Engineered Subunit Vaccine Sale Price by Company
3.4 Key Manufacturers Gene Engineered Subunit Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Gene Engineered Subunit Vaccine Product Location Distribution
3.4.2 Players Gene Engineered Subunit Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR GENE ENGINEERED SUBUNIT VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Gene Engineered Subunit Vaccine Market Size by Geographic Region (2019-2024)
4.1.1 Global Gene Engineered Subunit Vaccine Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Gene Engineered Subunit Vaccine Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Gene Engineered Subunit Vaccine Market Size by Country/Region (2019-2024)
4.2.1 Global Gene Engineered Subunit Vaccine Annual Sales by Country/Region (2019-2024)
4.2.2 Global Gene Engineered Subunit Vaccine Annual Revenue by Country/Region (2019-2024)
4.3 Americas Gene Engineered Subunit Vaccine Sales Growth
4.4 APAC Gene Engineered Subunit Vaccine Sales Growth
4.5 Europe Gene Engineered Subunit Vaccine Sales Growth
4.6 Middle East & Africa Gene Engineered Subunit Vaccine Sales Growth
5 AMERICAS
5.1 Americas Gene Engineered Subunit Vaccine Sales by Country
5.1.1 Americas Gene Engineered Subunit Vaccine Sales by Country (2019-2024)
5.1.2 Americas Gene Engineered Subunit Vaccine Revenue by Country (2019-2024)
5.2 Americas Gene Engineered Subunit Vaccine Sales by Type
5.3 Americas Gene Engineered Subunit Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gene Engineered Subunit Vaccine Sales by Region
6.1.1 APAC Gene Engineered Subunit Vaccine Sales by Region (2019-2024)
6.1.2 APAC Gene Engineered Subunit Vaccine Revenue by Region (2019-2024)
6.2 APAC Gene Engineered Subunit Vaccine Sales by Type
6.3 APAC Gene Engineered Subunit Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Gene Engineered Subunit Vaccine by Country
7.1.1 Europe Gene Engineered Subunit Vaccine Sales by Country (2019-2024)
7.1.2 Europe Gene Engineered Subunit Vaccine Revenue by Country (2019-2024)
7.2 Europe Gene Engineered Subunit Vaccine Sales by Type
7.3 Europe Gene Engineered Subunit Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Gene Engineered Subunit Vaccine by Country
8.1.1 Middle East & Africa Gene Engineered Subunit Vaccine Sales by Country (2019-2024)
8.1.2 Middle East & Africa Gene Engineered Subunit Vaccine Revenue by Country (2019-2024)
8.2 Middle East & Africa Gene Engineered Subunit Vaccine Sales by Type
8.3 Middle East & Africa Gene Engineered Subunit Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Gene Engineered Subunit Vaccine
10.3 Manufacturing Process Analysis of Gene Engineered Subunit Vaccine
10.4 Industry Chain Structure of Gene Engineered Subunit Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Gene Engineered Subunit Vaccine Distributors
11.3 Gene Engineered Subunit Vaccine Customer
12 WORLD FORECAST REVIEW FOR GENE ENGINEERED SUBUNIT VACCINE BY GEOGRAPHIC REGION
12.1 Global Gene Engineered Subunit Vaccine Market Size Forecast by Region
12.1.1 Global Gene Engineered Subunit Vaccine Forecast by Region (2025-2030)
12.1.2 Global Gene Engineered Subunit Vaccine Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Gene Engineered Subunit Vaccine Forecast by Type
12.7 Global Gene Engineered Subunit Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.1.3 Merck Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.2.3 GSK Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Tiantan
13.3.1 Tiantan Company Information
13.3.2 Tiantan Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.3.3 Tiantan Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Tiantan Main Business Overview
13.3.5 Tiantan Latest Developments
13.4 Pulike
13.4.1 Pulike Company Information
13.4.2 Pulike Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.4.3 Pulike Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pulike Main Business Overview
13.4.5 Pulike Latest Developments
13.5 Greffex
13.5.1 Greffex Company Information
13.5.2 Greffex Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.5.3 Greffex Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Greffex Main Business Overview
13.5.5 Greffex Latest Developments
13.6 CureVac
13.6.1 CureVac Company Information
13.6.2 CureVac Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.6.3 CureVac Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 CureVac Main Business Overview
13.6.5 CureVac Latest Developments
13.7 Yebio
13.7.1 Yebio Company Information
13.7.2 Yebio Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.7.3 Yebio Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Yebio Main Business Overview
13.7.5 Yebio Latest Developments
13.8 Sanofi Pasteur SA
13.8.1 Sanofi Pasteur SA Company Information
13.8.2 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.8.3 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Sanofi Pasteur SA Main Business Overview
13.8.5 Sanofi Pasteur SA Latest Developments
13.9 Virbac
13.9.1 Virbac Company Information
13.9.2 Virbac Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.9.3 Virbac Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Virbac Main Business Overview
13.9.5 Virbac Latest Developments
13.10 Pfizer Inc.
13.10.1 Pfizer Inc. Company Information
13.10.2 Pfizer Inc. Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.10.3 Pfizer Inc. Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Pfizer Inc. Main Business Overview
13.10.5 Pfizer Inc. Latest Developments
13.11 Walvax Biotechnology
13.11.1 Walvax Biotechnology Company Information
13.11.2 Walvax Biotechnology Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.11.3 Walvax Biotechnology Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Walvax Biotechnology Main Business Overview
13.11.5 Walvax Biotechnology Latest Developments
13.12 Kontec
13.12.1 Kontec Company Information
13.12.2 Kontec Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.12.3 Kontec Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Kontec Main Business Overview
13.12.5 Kontec Latest Developments
13.13 Novavax
13.13.1 Novavax Company Information
13.13.2 Novavax Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.13.3 Novavax Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Novavax Main Business Overview
13.13.5 Novavax Latest Developments
13.14 Sanofi Pasteur
13.14.1 Sanofi Pasteur Company Information
13.14.2 Sanofi Pasteur Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.14.3 Sanofi Pasteur Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Sanofi Pasteur Main Business Overview
13.14.5 Sanofi Pasteur Latest Developments
13.15 Bharat Biotech
13.15.1 Bharat Biotech Company Information
13.15.2 Bharat Biotech Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.15.3 Bharat Biotech Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Bharat Biotech Main Business Overview
13.15.5 Bharat Biotech Latest Developments
13.16 GlaxoSmithKline
13.16.1 GlaxoSmithKline Company Information
13.16.2 GlaxoSmithKline Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.16.3 GlaxoSmithKline Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 GlaxoSmithKline Main Business Overview
13.16.5 GlaxoSmithKline Latest Developments
13.17 Pfizer
13.17.1 Pfizer Company Information
13.17.2 Pfizer Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.17.3 Pfizer Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Pfizer Main Business Overview
13.17.5 Pfizer Latest Developments
13.18 Moderna
13.18.1 Moderna Company Information
13.18.2 Moderna Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.18.3 Moderna Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Moderna Main Business Overview
13.18.5 Moderna Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Gene Engineered Subunit Vaccine Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Gene Engineered Subunit Vaccine by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Gene Engineered Subunit Vaccine by Country/Region, 2019, 2023 & 2030
2.2 Gene Engineered Subunit Vaccine Segment by Type
2.2.1 Therapeutic Gene Engineered Subunit Vaccine
2.2.2 Preventative Gene Engineered Subunit Vaccine
2.3 Gene Engineered Subunit Vaccine Sales by Type
2.3.1 Global Gene Engineered Subunit Vaccine Sales Market Share by Type (2019-2024)
2.3.2 Global Gene Engineered Subunit Vaccine Revenue and Market Share by Type (2019-2024)
2.3.3 Global Gene Engineered Subunit Vaccine Sale Price by Type (2019-2024)
2.4 Gene Engineered Subunit Vaccine Segment by Application
2.4.1 Human Use
2.4.2 Veterinary Use
2.5 Gene Engineered Subunit Vaccine Sales by Application
2.5.1 Global Gene Engineered Subunit Vaccine Sale Market Share by Application (2019-2024)
2.5.2 Global Gene Engineered Subunit Vaccine Revenue and Market Share by Application (2019-2024)
2.5.3 Global Gene Engineered Subunit Vaccine Sale Price by Application (2019-2024)
3 GLOBAL GENE ENGINEERED SUBUNIT VACCINE BY COMPANY
3.1 Global Gene Engineered Subunit Vaccine Breakdown Data by Company
3.1.1 Global Gene Engineered Subunit Vaccine Annual Sales by Company (2019-2024)
3.1.2 Global Gene Engineered Subunit Vaccine Sales Market Share by Company (2019-2024)
3.2 Global Gene Engineered Subunit Vaccine Annual Revenue by Company (2019-2024)
3.2.1 Global Gene Engineered Subunit Vaccine Revenue by Company (2019-2024)
3.2.2 Global Gene Engineered Subunit Vaccine Revenue Market Share by Company (2019-2024)
3.3 Global Gene Engineered Subunit Vaccine Sale Price by Company
3.4 Key Manufacturers Gene Engineered Subunit Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Gene Engineered Subunit Vaccine Product Location Distribution
3.4.2 Players Gene Engineered Subunit Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR GENE ENGINEERED SUBUNIT VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Gene Engineered Subunit Vaccine Market Size by Geographic Region (2019-2024)
4.1.1 Global Gene Engineered Subunit Vaccine Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Gene Engineered Subunit Vaccine Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Gene Engineered Subunit Vaccine Market Size by Country/Region (2019-2024)
4.2.1 Global Gene Engineered Subunit Vaccine Annual Sales by Country/Region (2019-2024)
4.2.2 Global Gene Engineered Subunit Vaccine Annual Revenue by Country/Region (2019-2024)
4.3 Americas Gene Engineered Subunit Vaccine Sales Growth
4.4 APAC Gene Engineered Subunit Vaccine Sales Growth
4.5 Europe Gene Engineered Subunit Vaccine Sales Growth
4.6 Middle East & Africa Gene Engineered Subunit Vaccine Sales Growth
5 AMERICAS
5.1 Americas Gene Engineered Subunit Vaccine Sales by Country
5.1.1 Americas Gene Engineered Subunit Vaccine Sales by Country (2019-2024)
5.1.2 Americas Gene Engineered Subunit Vaccine Revenue by Country (2019-2024)
5.2 Americas Gene Engineered Subunit Vaccine Sales by Type
5.3 Americas Gene Engineered Subunit Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gene Engineered Subunit Vaccine Sales by Region
6.1.1 APAC Gene Engineered Subunit Vaccine Sales by Region (2019-2024)
6.1.2 APAC Gene Engineered Subunit Vaccine Revenue by Region (2019-2024)
6.2 APAC Gene Engineered Subunit Vaccine Sales by Type
6.3 APAC Gene Engineered Subunit Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Gene Engineered Subunit Vaccine by Country
7.1.1 Europe Gene Engineered Subunit Vaccine Sales by Country (2019-2024)
7.1.2 Europe Gene Engineered Subunit Vaccine Revenue by Country (2019-2024)
7.2 Europe Gene Engineered Subunit Vaccine Sales by Type
7.3 Europe Gene Engineered Subunit Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Gene Engineered Subunit Vaccine by Country
8.1.1 Middle East & Africa Gene Engineered Subunit Vaccine Sales by Country (2019-2024)
8.1.2 Middle East & Africa Gene Engineered Subunit Vaccine Revenue by Country (2019-2024)
8.2 Middle East & Africa Gene Engineered Subunit Vaccine Sales by Type
8.3 Middle East & Africa Gene Engineered Subunit Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Gene Engineered Subunit Vaccine
10.3 Manufacturing Process Analysis of Gene Engineered Subunit Vaccine
10.4 Industry Chain Structure of Gene Engineered Subunit Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Gene Engineered Subunit Vaccine Distributors
11.3 Gene Engineered Subunit Vaccine Customer
12 WORLD FORECAST REVIEW FOR GENE ENGINEERED SUBUNIT VACCINE BY GEOGRAPHIC REGION
12.1 Global Gene Engineered Subunit Vaccine Market Size Forecast by Region
12.1.1 Global Gene Engineered Subunit Vaccine Forecast by Region (2025-2030)
12.1.2 Global Gene Engineered Subunit Vaccine Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Gene Engineered Subunit Vaccine Forecast by Type
12.7 Global Gene Engineered Subunit Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.1.3 Merck Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.2.3 GSK Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Tiantan
13.3.1 Tiantan Company Information
13.3.2 Tiantan Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.3.3 Tiantan Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Tiantan Main Business Overview
13.3.5 Tiantan Latest Developments
13.4 Pulike
13.4.1 Pulike Company Information
13.4.2 Pulike Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.4.3 Pulike Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pulike Main Business Overview
13.4.5 Pulike Latest Developments
13.5 Greffex
13.5.1 Greffex Company Information
13.5.2 Greffex Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.5.3 Greffex Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Greffex Main Business Overview
13.5.5 Greffex Latest Developments
13.6 CureVac
13.6.1 CureVac Company Information
13.6.2 CureVac Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.6.3 CureVac Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 CureVac Main Business Overview
13.6.5 CureVac Latest Developments
13.7 Yebio
13.7.1 Yebio Company Information
13.7.2 Yebio Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.7.3 Yebio Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Yebio Main Business Overview
13.7.5 Yebio Latest Developments
13.8 Sanofi Pasteur SA
13.8.1 Sanofi Pasteur SA Company Information
13.8.2 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.8.3 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Sanofi Pasteur SA Main Business Overview
13.8.5 Sanofi Pasteur SA Latest Developments
13.9 Virbac
13.9.1 Virbac Company Information
13.9.2 Virbac Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.9.3 Virbac Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Virbac Main Business Overview
13.9.5 Virbac Latest Developments
13.10 Pfizer Inc.
13.10.1 Pfizer Inc. Company Information
13.10.2 Pfizer Inc. Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.10.3 Pfizer Inc. Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Pfizer Inc. Main Business Overview
13.10.5 Pfizer Inc. Latest Developments
13.11 Walvax Biotechnology
13.11.1 Walvax Biotechnology Company Information
13.11.2 Walvax Biotechnology Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.11.3 Walvax Biotechnology Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Walvax Biotechnology Main Business Overview
13.11.5 Walvax Biotechnology Latest Developments
13.12 Kontec
13.12.1 Kontec Company Information
13.12.2 Kontec Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.12.3 Kontec Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Kontec Main Business Overview
13.12.5 Kontec Latest Developments
13.13 Novavax
13.13.1 Novavax Company Information
13.13.2 Novavax Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.13.3 Novavax Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Novavax Main Business Overview
13.13.5 Novavax Latest Developments
13.14 Sanofi Pasteur
13.14.1 Sanofi Pasteur Company Information
13.14.2 Sanofi Pasteur Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.14.3 Sanofi Pasteur Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Sanofi Pasteur Main Business Overview
13.14.5 Sanofi Pasteur Latest Developments
13.15 Bharat Biotech
13.15.1 Bharat Biotech Company Information
13.15.2 Bharat Biotech Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.15.3 Bharat Biotech Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Bharat Biotech Main Business Overview
13.15.5 Bharat Biotech Latest Developments
13.16 GlaxoSmithKline
13.16.1 GlaxoSmithKline Company Information
13.16.2 GlaxoSmithKline Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.16.3 GlaxoSmithKline Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 GlaxoSmithKline Main Business Overview
13.16.5 GlaxoSmithKline Latest Developments
13.17 Pfizer
13.17.1 Pfizer Company Information
13.17.2 Pfizer Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.17.3 Pfizer Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Pfizer Main Business Overview
13.17.5 Pfizer Latest Developments
13.18 Moderna
13.18.1 Moderna Company Information
13.18.2 Moderna Gene Engineered Subunit Vaccine Product Portfolios and Specifications
13.18.3 Moderna Gene Engineered Subunit Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Moderna Main Business Overview
13.18.5 Moderna Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Gene Engineered Subunit Vaccine Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Gene Engineered Subunit Vaccine Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Therapeutic Gene Engineered Subunit Vaccine
Table 4. Major Players of Preventative Gene Engineered Subunit Vaccine
Table 5. Global Gene Engineered Subunit Vaccine Sales by Type (2019-2024) & (K Dose)
Table 6. Global Gene Engineered Subunit Vaccine Sales Market Share by Type (2019-2024)
Table 7. Global Gene Engineered Subunit Vaccine Revenue by Type (2019-2024) & ($ million)
Table 8. Global Gene Engineered Subunit Vaccine Revenue Market Share by Type (2019-2024)
Table 9. Global Gene Engineered Subunit Vaccine Sale Price by Type (2019-2024) & (US$/Dose)
Table 10. Global Gene Engineered Subunit Vaccine Sales by Application (2019-2024) & (K Dose)
Table 11. Global Gene Engineered Subunit Vaccine Sales Market Share by Application (2019-2024)
Table 12. Global Gene Engineered Subunit Vaccine Revenue by Application (2019-2024)
Table 13. Global Gene Engineered Subunit Vaccine Revenue Market Share by Application (2019-2024)
Table 14. Global Gene Engineered Subunit Vaccine Sale Price by Application (2019-2024) & (US$/Dose)
Table 15. Global Gene Engineered Subunit Vaccine Sales by Company (2019-2024) & (K Dose)
Table 16. Global Gene Engineered Subunit Vaccine Sales Market Share by Company (2019-2024)
Table 17. Global Gene Engineered Subunit Vaccine Revenue by Company (2019-2024) ($ Millions)
Table 18. Global Gene Engineered Subunit Vaccine Revenue Market Share by Company (2019-2024)
Table 19. Global Gene Engineered Subunit Vaccine Sale Price by Company (2019-2024) & (US$/Dose)
Table 20. Key Manufacturers Gene Engineered Subunit Vaccine Producing Area Distribution and Sales Area
Table 21. Players Gene Engineered Subunit Vaccine Products Offered
Table 22. Gene Engineered Subunit Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Gene Engineered Subunit Vaccine Sales by Geographic Region (2019-2024) & (K Dose)
Table 26. Global Gene Engineered Subunit Vaccine Sales Market Share Geographic Region (2019-2024)
Table 27. Global Gene Engineered Subunit Vaccine Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Gene Engineered Subunit Vaccine Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Gene Engineered Subunit Vaccine Sales by Country/Region (2019-2024) & (K Dose)
Table 30. Global Gene Engineered Subunit Vaccine Sales Market Share by Country/Region (2019-2024)
Table 31. Global Gene Engineered Subunit Vaccine Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Gene Engineered Subunit Vaccine Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Gene Engineered Subunit Vaccine Sales by Country (2019-2024) & (K Dose)
Table 34. Americas Gene Engineered Subunit Vaccine Sales Market Share by Country (2019-2024)
Table 35. Americas Gene Engineered Subunit Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas Gene Engineered Subunit Vaccine Revenue Market Share by Country (2019-2024)
Table 37. Americas Gene Engineered Subunit Vaccine Sales by Type (2019-2024) & (K Dose)
Table 38. Americas Gene Engineered Subunit Vaccine Sales by Application (2019-2024) & (K Dose)
Table 39. APAC Gene Engineered Subunit Vaccine Sales by Region (2019-2024) & (K Dose)
Table 40. APAC Gene Engineered Subunit Vaccine Sales Market Share by Region (2019-2024)
Table 41. APAC Gene Engineered Subunit Vaccine Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC Gene Engineered Subunit Vaccine Revenue Market Share by Region (2019-2024)
Table 43. APAC Gene Engineered Subunit Vaccine Sales by Type (2019-2024) & (K Dose)
Table 44. APAC Gene Engineered Subunit Vaccine Sales by Application (2019-2024) & (K Dose)
Table 45. Europe Gene Engineered Subunit Vaccine Sales by Country (2019-2024) & (K Dose)
Table 46. Europe Gene Engineered Subunit Vaccine Sales Market Share by Country (2019-2024)
Table 47. Europe Gene Engineered Subunit Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe Gene Engineered Subunit Vaccine Revenue Market Share by Country (2019-2024)
Table 49. Europe Gene Engineered Subunit Vaccine Sales by Type (2019-2024) & (K Dose)
Table 50. Europe Gene Engineered Subunit Vaccine Sales by Application (2019-2024) & (K Dose)
Table 51. Middle East & Africa Gene Engineered Subunit Vaccine Sales by Country (2019-2024) & (K Dose)
Table 52. Middle East & Africa Gene Engineered Subunit Vaccine Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa Gene Engineered Subunit Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa Gene Engineered Subunit Vaccine Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa Gene Engineered Subunit Vaccine Sales by Type (2019-2024) & (K Dose)
Table 56. Middle East & Africa Gene Engineered Subunit Vaccine Sales by Application (2019-2024) & (K Dose)
Table 57. Key Market Drivers & Growth Opportunities of Gene Engineered Subunit Vaccine
Table 58. Key Market Challenges & Risks of Gene Engineered Subunit Vaccine
Table 59. Key Industry Trends of Gene Engineered Subunit Vaccine
Table 60. Gene Engineered Subunit Vaccine Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Gene Engineered Subunit Vaccine Distributors List
Table 63. Gene Engineered Subunit Vaccine Customer List
Table 64. Global Gene Engineered Subunit Vaccine Sales Forecast by Region (2025-2030) & (K Dose)
Table 65. Global Gene Engineered Subunit Vaccine Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas Gene Engineered Subunit Vaccine Sales Forecast by Country (2025-2030) & (K Dose)
Table 67. Americas Gene Engineered Subunit Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC Gene Engineered Subunit Vaccine Sales Forecast by Region (2025-2030) & (K Dose)
Table 69. APAC Gene Engineered Subunit Vaccine Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe Gene Engineered Subunit Vaccine Sales Forecast by Country (2025-2030) & (K Dose)
Table 71. Europe Gene Engineered Subunit Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa Gene Engineered Subunit Vaccine Sales Forecast by Country (2025-2030) & (K Dose)
Table 73. Middle East & Africa Gene Engineered Subunit Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global Gene Engineered Subunit Vaccine Sales Forecast by Type (2025-2030) & (K Dose)
Table 75. Global Gene Engineered Subunit Vaccine Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global Gene Engineered Subunit Vaccine Sales Forecast by Application (2025-2030) & (K Dose)
Table 77. Global Gene Engineered Subunit Vaccine Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. Merck Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. Merck Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 80. Merck Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 81. Merck Main Business
Table 82. Merck Latest Developments
Table 83. GSK Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. GSK Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 85. GSK Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 86. GSK Main Business
Table 87. GSK Latest Developments
Table 88. Tiantan Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Tiantan Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 90. Tiantan Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 91. Tiantan Main Business
Table 92. Tiantan Latest Developments
Table 93. Pulike Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. Pulike Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 95. Pulike Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 96. Pulike Main Business
Table 97. Pulike Latest Developments
Table 98. Greffex Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. Greffex Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 100. Greffex Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 101. Greffex Main Business
Table 102. Greffex Latest Developments
Table 103. CureVac Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. CureVac Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 105. CureVac Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 106. CureVac Main Business
Table 107. CureVac Latest Developments
Table 108. Yebio Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Yebio Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 110. Yebio Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 111. Yebio Main Business
Table 112. Yebio Latest Developments
Table 113. Sanofi Pasteur SA Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Sanofi Pasteur SA Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 115. Sanofi Pasteur SA Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 116. Sanofi Pasteur SA Main Business
Table 117. Sanofi Pasteur SA Latest Developments
Table 118. Virbac Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. Virbac Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 120. Virbac Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 121. Virbac Main Business
Table 122. Virbac Latest Developments
Table 123. Pfizer Inc. Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Pfizer Inc. Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 125. Pfizer Inc. Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 126. Pfizer Inc. Main Business
Table 127. Pfizer Inc. Latest Developments
Table 128. Walvax Biotechnology Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 129. Walvax Biotechnology Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 130. Walvax Biotechnology Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 131. Walvax Biotechnology Main Business
Table 132. Walvax Biotechnology Latest Developments
Table 133. Kontec Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 134. Kontec Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 135. Kontec Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 136. Kontec Main Business
Table 137. Kontec Latest Developments
Table 138. Novavax Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 139. Novavax Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 140. Novavax Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 141. Novavax Main Business
Table 142. Novavax Latest Developments
Table 143. Sanofi Pasteur Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 144. Sanofi Pasteur Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 145. Sanofi Pasteur Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 146. Sanofi Pasteur Main Business
Table 147. Sanofi Pasteur Latest Developments
Table 148. Bharat Biotech Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 149. Bharat Biotech Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 150. Bharat Biotech Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 151. Bharat Biotech Main Business
Table 152. Bharat Biotech Latest Developments
Table 153. GlaxoSmithKline Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 154. GlaxoSmithKline Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 155. GlaxoSmithKline Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 156. GlaxoSmithKline Main Business
Table 157. GlaxoSmithKline Latest Developments
Table 158. Pfizer Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 159. Pfizer Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 160. Pfizer Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 161. Pfizer Main Business
Table 162. Pfizer Latest Developments
Table 163. Moderna Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 164. Moderna Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 165. Moderna Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 166. Moderna Main Business
Table 167. Moderna Latest Developments
Table 1. Gene Engineered Subunit Vaccine Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Gene Engineered Subunit Vaccine Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Therapeutic Gene Engineered Subunit Vaccine
Table 4. Major Players of Preventative Gene Engineered Subunit Vaccine
Table 5. Global Gene Engineered Subunit Vaccine Sales by Type (2019-2024) & (K Dose)
Table 6. Global Gene Engineered Subunit Vaccine Sales Market Share by Type (2019-2024)
Table 7. Global Gene Engineered Subunit Vaccine Revenue by Type (2019-2024) & ($ million)
Table 8. Global Gene Engineered Subunit Vaccine Revenue Market Share by Type (2019-2024)
Table 9. Global Gene Engineered Subunit Vaccine Sale Price by Type (2019-2024) & (US$/Dose)
Table 10. Global Gene Engineered Subunit Vaccine Sales by Application (2019-2024) & (K Dose)
Table 11. Global Gene Engineered Subunit Vaccine Sales Market Share by Application (2019-2024)
Table 12. Global Gene Engineered Subunit Vaccine Revenue by Application (2019-2024)
Table 13. Global Gene Engineered Subunit Vaccine Revenue Market Share by Application (2019-2024)
Table 14. Global Gene Engineered Subunit Vaccine Sale Price by Application (2019-2024) & (US$/Dose)
Table 15. Global Gene Engineered Subunit Vaccine Sales by Company (2019-2024) & (K Dose)
Table 16. Global Gene Engineered Subunit Vaccine Sales Market Share by Company (2019-2024)
Table 17. Global Gene Engineered Subunit Vaccine Revenue by Company (2019-2024) ($ Millions)
Table 18. Global Gene Engineered Subunit Vaccine Revenue Market Share by Company (2019-2024)
Table 19. Global Gene Engineered Subunit Vaccine Sale Price by Company (2019-2024) & (US$/Dose)
Table 20. Key Manufacturers Gene Engineered Subunit Vaccine Producing Area Distribution and Sales Area
Table 21. Players Gene Engineered Subunit Vaccine Products Offered
Table 22. Gene Engineered Subunit Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Gene Engineered Subunit Vaccine Sales by Geographic Region (2019-2024) & (K Dose)
Table 26. Global Gene Engineered Subunit Vaccine Sales Market Share Geographic Region (2019-2024)
Table 27. Global Gene Engineered Subunit Vaccine Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Gene Engineered Subunit Vaccine Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Gene Engineered Subunit Vaccine Sales by Country/Region (2019-2024) & (K Dose)
Table 30. Global Gene Engineered Subunit Vaccine Sales Market Share by Country/Region (2019-2024)
Table 31. Global Gene Engineered Subunit Vaccine Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Gene Engineered Subunit Vaccine Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Gene Engineered Subunit Vaccine Sales by Country (2019-2024) & (K Dose)
Table 34. Americas Gene Engineered Subunit Vaccine Sales Market Share by Country (2019-2024)
Table 35. Americas Gene Engineered Subunit Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas Gene Engineered Subunit Vaccine Revenue Market Share by Country (2019-2024)
Table 37. Americas Gene Engineered Subunit Vaccine Sales by Type (2019-2024) & (K Dose)
Table 38. Americas Gene Engineered Subunit Vaccine Sales by Application (2019-2024) & (K Dose)
Table 39. APAC Gene Engineered Subunit Vaccine Sales by Region (2019-2024) & (K Dose)
Table 40. APAC Gene Engineered Subunit Vaccine Sales Market Share by Region (2019-2024)
Table 41. APAC Gene Engineered Subunit Vaccine Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC Gene Engineered Subunit Vaccine Revenue Market Share by Region (2019-2024)
Table 43. APAC Gene Engineered Subunit Vaccine Sales by Type (2019-2024) & (K Dose)
Table 44. APAC Gene Engineered Subunit Vaccine Sales by Application (2019-2024) & (K Dose)
Table 45. Europe Gene Engineered Subunit Vaccine Sales by Country (2019-2024) & (K Dose)
Table 46. Europe Gene Engineered Subunit Vaccine Sales Market Share by Country (2019-2024)
Table 47. Europe Gene Engineered Subunit Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe Gene Engineered Subunit Vaccine Revenue Market Share by Country (2019-2024)
Table 49. Europe Gene Engineered Subunit Vaccine Sales by Type (2019-2024) & (K Dose)
Table 50. Europe Gene Engineered Subunit Vaccine Sales by Application (2019-2024) & (K Dose)
Table 51. Middle East & Africa Gene Engineered Subunit Vaccine Sales by Country (2019-2024) & (K Dose)
Table 52. Middle East & Africa Gene Engineered Subunit Vaccine Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa Gene Engineered Subunit Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa Gene Engineered Subunit Vaccine Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa Gene Engineered Subunit Vaccine Sales by Type (2019-2024) & (K Dose)
Table 56. Middle East & Africa Gene Engineered Subunit Vaccine Sales by Application (2019-2024) & (K Dose)
Table 57. Key Market Drivers & Growth Opportunities of Gene Engineered Subunit Vaccine
Table 58. Key Market Challenges & Risks of Gene Engineered Subunit Vaccine
Table 59. Key Industry Trends of Gene Engineered Subunit Vaccine
Table 60. Gene Engineered Subunit Vaccine Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Gene Engineered Subunit Vaccine Distributors List
Table 63. Gene Engineered Subunit Vaccine Customer List
Table 64. Global Gene Engineered Subunit Vaccine Sales Forecast by Region (2025-2030) & (K Dose)
Table 65. Global Gene Engineered Subunit Vaccine Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas Gene Engineered Subunit Vaccine Sales Forecast by Country (2025-2030) & (K Dose)
Table 67. Americas Gene Engineered Subunit Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC Gene Engineered Subunit Vaccine Sales Forecast by Region (2025-2030) & (K Dose)
Table 69. APAC Gene Engineered Subunit Vaccine Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe Gene Engineered Subunit Vaccine Sales Forecast by Country (2025-2030) & (K Dose)
Table 71. Europe Gene Engineered Subunit Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa Gene Engineered Subunit Vaccine Sales Forecast by Country (2025-2030) & (K Dose)
Table 73. Middle East & Africa Gene Engineered Subunit Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global Gene Engineered Subunit Vaccine Sales Forecast by Type (2025-2030) & (K Dose)
Table 75. Global Gene Engineered Subunit Vaccine Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global Gene Engineered Subunit Vaccine Sales Forecast by Application (2025-2030) & (K Dose)
Table 77. Global Gene Engineered Subunit Vaccine Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. Merck Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. Merck Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 80. Merck Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 81. Merck Main Business
Table 82. Merck Latest Developments
Table 83. GSK Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. GSK Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 85. GSK Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 86. GSK Main Business
Table 87. GSK Latest Developments
Table 88. Tiantan Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Tiantan Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 90. Tiantan Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 91. Tiantan Main Business
Table 92. Tiantan Latest Developments
Table 93. Pulike Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. Pulike Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 95. Pulike Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 96. Pulike Main Business
Table 97. Pulike Latest Developments
Table 98. Greffex Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. Greffex Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 100. Greffex Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 101. Greffex Main Business
Table 102. Greffex Latest Developments
Table 103. CureVac Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. CureVac Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 105. CureVac Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 106. CureVac Main Business
Table 107. CureVac Latest Developments
Table 108. Yebio Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Yebio Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 110. Yebio Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 111. Yebio Main Business
Table 112. Yebio Latest Developments
Table 113. Sanofi Pasteur SA Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Sanofi Pasteur SA Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 115. Sanofi Pasteur SA Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 116. Sanofi Pasteur SA Main Business
Table 117. Sanofi Pasteur SA Latest Developments
Table 118. Virbac Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. Virbac Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 120. Virbac Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 121. Virbac Main Business
Table 122. Virbac Latest Developments
Table 123. Pfizer Inc. Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Pfizer Inc. Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 125. Pfizer Inc. Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 126. Pfizer Inc. Main Business
Table 127. Pfizer Inc. Latest Developments
Table 128. Walvax Biotechnology Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 129. Walvax Biotechnology Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 130. Walvax Biotechnology Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 131. Walvax Biotechnology Main Business
Table 132. Walvax Biotechnology Latest Developments
Table 133. Kontec Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 134. Kontec Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 135. Kontec Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 136. Kontec Main Business
Table 137. Kontec Latest Developments
Table 138. Novavax Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 139. Novavax Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 140. Novavax Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 141. Novavax Main Business
Table 142. Novavax Latest Developments
Table 143. Sanofi Pasteur Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 144. Sanofi Pasteur Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 145. Sanofi Pasteur Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 146. Sanofi Pasteur Main Business
Table 147. Sanofi Pasteur Latest Developments
Table 148. Bharat Biotech Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 149. Bharat Biotech Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 150. Bharat Biotech Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 151. Bharat Biotech Main Business
Table 152. Bharat Biotech Latest Developments
Table 153. GlaxoSmithKline Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 154. GlaxoSmithKline Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 155. GlaxoSmithKline Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 156. GlaxoSmithKline Main Business
Table 157. GlaxoSmithKline Latest Developments
Table 158. Pfizer Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 159. Pfizer Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 160. Pfizer Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 161. Pfizer Main Business
Table 162. Pfizer Latest Developments
Table 163. Moderna Basic Information, Gene Engineered Subunit Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 164. Moderna Gene Engineered Subunit Vaccine Product Portfolios and Specifications
Table 165. Moderna Gene Engineered Subunit Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 166. Moderna Main Business
Table 167. Moderna Latest Developments
LIST OF FIGURES
Figure 1. Picture of Gene Engineered Subunit Vaccine
Figure 2. Gene Engineered Subunit Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Gene Engineered Subunit Vaccine Sales Growth Rate 2019-2030 (K Dose)
Figure 7. Global Gene Engineered Subunit Vaccine Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Gene Engineered Subunit Vaccine Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Therapeutic Gene Engineered Subunit Vaccine
Figure 10. Product Picture of Preventative Gene Engineered Subunit Vaccine
Figure 11. Global Gene Engineered Subunit Vaccine Sales Market Share by Type in 2023
Figure 12. Global Gene Engineered Subunit Vaccine Revenue Market Share by Type (2019-2024)
Figure 13. Gene Engineered Subunit Vaccine Consumed in Human Use
Figure 14. Global Gene Engineered Subunit Vaccine Market: Human Use (2019-2024) & (K Dose)
Figure 15. Gene Engineered Subunit Vaccine Consumed in Veterinary Use
Figure 16. Global Gene Engineered Subunit Vaccine Market: Veterinary Use (2019-2024) & (K Dose)
Figure 17. Global Gene Engineered Subunit Vaccine Sales Market Share by Application (2023)
Figure 18. Global Gene Engineered Subunit Vaccine Revenue Market Share by Application in 2023
Figure 19. Gene Engineered Subunit Vaccine Sales Market by Company in 2023 (K Dose)
Figure 20. Global Gene Engineered Subunit Vaccine Sales Market Share by Company in 2023
Figure 21. Gene Engineered Subunit Vaccine Revenue Market by Company in 2023 ($ Million)
Figure 22. Global Gene Engineered Subunit Vaccine Revenue Market Share by Company in 2023
Figure 23. Global Gene Engineered Subunit Vaccine Sales Market Share by Geographic Region (2019-2024)
Figure 24. Global Gene Engineered Subunit Vaccine Revenue Market Share by Geographic Region in 2023
Figure 25. Americas Gene Engineered Subunit Vaccine Sales 2019-2024 (K Dose)
Figure 26. Americas Gene Engineered Subunit Vaccine Revenue 2019-2024 ($ Millions)
Figure 27. APAC Gene Engineered Subunit Vaccine Sales 2019-2024 (K Dose)
Figure 28. APAC Gene Engineered Subunit Vaccine Revenue 2019-2024 ($ Millions)
Figure 29. Europe Gene Engineered Subunit Vaccine Sales 2019-2024 (K Dose)
Figure 30. Europe Gene Engineered Subunit Vaccine Revenue 2019-2024 ($ Millions)
Figure 31. Middle East & Africa Gene Engineered Subunit Vaccine Sales 2019-2024 (K Dose)
Figure 32. Middle East & Africa Gene Engineered Subunit Vaccine Revenue 2019-2024 ($ Millions)
Figure 33. Americas Gene Engineered Subunit Vaccine Sales Market Share by Country in 2023
Figure 34. Americas Gene Engineered Subunit Vaccine Revenue Market Share by Country in 2023
Figure 35. Americas Gene Engineered Subunit Vaccine Sales Market Share by Type (2019-2024)
Figure 36. Americas Gene Engineered Subunit Vaccine Sales Market Share by Application (2019-2024)
Figure 37. United States Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 38. Canada Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 39. Mexico Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 40. Brazil Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 41. APAC Gene Engineered Subunit Vaccine Sales Market Share by Region in 2023
Figure 42. APAC Gene Engineered Subunit Vaccine Revenue Market Share by Regions in 2023
Figure 43. APAC Gene Engineered Subunit Vaccine Sales Market Share by Type (2019-2024)
Figure 44. APAC Gene Engineered Subunit Vaccine Sales Market Share by Application (2019-2024)
Figure 45. China Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 46. Japan Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 47. South Korea Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 48. Southeast Asia Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 49. India Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 50. Australia Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 51. China Taiwan Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 52. Europe Gene Engineered Subunit Vaccine Sales Market Share by Country in 2023
Figure 53. Europe Gene Engineered Subunit Vaccine Revenue Market Share by Country in 2023
Figure 54. Europe Gene Engineered Subunit Vaccine Sales Market Share by Type (2019-2024)
Figure 55. Europe Gene Engineered Subunit Vaccine Sales Market Share by Application (2019-2024)
Figure 56. Germany Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 57. France Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 58. UK Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 59. Italy Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 60. Russia Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 61. Middle East & Africa Gene Engineered Subunit Vaccine Sales Market Share by Country in 2023
Figure 62. Middle East & Africa Gene Engineered Subunit Vaccine Revenue Market Share by Country in 2023
Figure 63. Middle East & Africa Gene Engineered Subunit Vaccine Sales Market Share by Type (2019-2024)
Figure 64. Middle East & Africa Gene Engineered Subunit Vaccine Sales Market Share by Application (2019-2024)
Figure 65. Egypt Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 66. South Africa Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 67. Israel Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 68. Turkey Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 69. GCC Country Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Gene Engineered Subunit Vaccine in 2023
Figure 71. Manufacturing Process Analysis of Gene Engineered Subunit Vaccine
Figure 72. Industry Chain Structure of Gene Engineered Subunit Vaccine
Figure 73. Channels of Distribution
Figure 74. Global Gene Engineered Subunit Vaccine Sales Market Forecast by Region (2025-2030)
Figure 75. Global Gene Engineered Subunit Vaccine Revenue Market Share Forecast by Region (2025-2030)
Figure 76. Global Gene Engineered Subunit Vaccine Sales Market Share Forecast by Type (2025-2030)
Figure 77. Global Gene Engineered Subunit Vaccine Revenue Market Share Forecast by Type (2025-2030)
Figure 78. Global Gene Engineered Subunit Vaccine Sales Market Share Forecast by Application (2025-2030)
Figure 79. Global Gene Engineered Subunit Vaccine Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Gene Engineered Subunit Vaccine
Figure 2. Gene Engineered Subunit Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Gene Engineered Subunit Vaccine Sales Growth Rate 2019-2030 (K Dose)
Figure 7. Global Gene Engineered Subunit Vaccine Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Gene Engineered Subunit Vaccine Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Therapeutic Gene Engineered Subunit Vaccine
Figure 10. Product Picture of Preventative Gene Engineered Subunit Vaccine
Figure 11. Global Gene Engineered Subunit Vaccine Sales Market Share by Type in 2023
Figure 12. Global Gene Engineered Subunit Vaccine Revenue Market Share by Type (2019-2024)
Figure 13. Gene Engineered Subunit Vaccine Consumed in Human Use
Figure 14. Global Gene Engineered Subunit Vaccine Market: Human Use (2019-2024) & (K Dose)
Figure 15. Gene Engineered Subunit Vaccine Consumed in Veterinary Use
Figure 16. Global Gene Engineered Subunit Vaccine Market: Veterinary Use (2019-2024) & (K Dose)
Figure 17. Global Gene Engineered Subunit Vaccine Sales Market Share by Application (2023)
Figure 18. Global Gene Engineered Subunit Vaccine Revenue Market Share by Application in 2023
Figure 19. Gene Engineered Subunit Vaccine Sales Market by Company in 2023 (K Dose)
Figure 20. Global Gene Engineered Subunit Vaccine Sales Market Share by Company in 2023
Figure 21. Gene Engineered Subunit Vaccine Revenue Market by Company in 2023 ($ Million)
Figure 22. Global Gene Engineered Subunit Vaccine Revenue Market Share by Company in 2023
Figure 23. Global Gene Engineered Subunit Vaccine Sales Market Share by Geographic Region (2019-2024)
Figure 24. Global Gene Engineered Subunit Vaccine Revenue Market Share by Geographic Region in 2023
Figure 25. Americas Gene Engineered Subunit Vaccine Sales 2019-2024 (K Dose)
Figure 26. Americas Gene Engineered Subunit Vaccine Revenue 2019-2024 ($ Millions)
Figure 27. APAC Gene Engineered Subunit Vaccine Sales 2019-2024 (K Dose)
Figure 28. APAC Gene Engineered Subunit Vaccine Revenue 2019-2024 ($ Millions)
Figure 29. Europe Gene Engineered Subunit Vaccine Sales 2019-2024 (K Dose)
Figure 30. Europe Gene Engineered Subunit Vaccine Revenue 2019-2024 ($ Millions)
Figure 31. Middle East & Africa Gene Engineered Subunit Vaccine Sales 2019-2024 (K Dose)
Figure 32. Middle East & Africa Gene Engineered Subunit Vaccine Revenue 2019-2024 ($ Millions)
Figure 33. Americas Gene Engineered Subunit Vaccine Sales Market Share by Country in 2023
Figure 34. Americas Gene Engineered Subunit Vaccine Revenue Market Share by Country in 2023
Figure 35. Americas Gene Engineered Subunit Vaccine Sales Market Share by Type (2019-2024)
Figure 36. Americas Gene Engineered Subunit Vaccine Sales Market Share by Application (2019-2024)
Figure 37. United States Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 38. Canada Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 39. Mexico Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 40. Brazil Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 41. APAC Gene Engineered Subunit Vaccine Sales Market Share by Region in 2023
Figure 42. APAC Gene Engineered Subunit Vaccine Revenue Market Share by Regions in 2023
Figure 43. APAC Gene Engineered Subunit Vaccine Sales Market Share by Type (2019-2024)
Figure 44. APAC Gene Engineered Subunit Vaccine Sales Market Share by Application (2019-2024)
Figure 45. China Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 46. Japan Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 47. South Korea Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 48. Southeast Asia Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 49. India Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 50. Australia Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 51. China Taiwan Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 52. Europe Gene Engineered Subunit Vaccine Sales Market Share by Country in 2023
Figure 53. Europe Gene Engineered Subunit Vaccine Revenue Market Share by Country in 2023
Figure 54. Europe Gene Engineered Subunit Vaccine Sales Market Share by Type (2019-2024)
Figure 55. Europe Gene Engineered Subunit Vaccine Sales Market Share by Application (2019-2024)
Figure 56. Germany Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 57. France Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 58. UK Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 59. Italy Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 60. Russia Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 61. Middle East & Africa Gene Engineered Subunit Vaccine Sales Market Share by Country in 2023
Figure 62. Middle East & Africa Gene Engineered Subunit Vaccine Revenue Market Share by Country in 2023
Figure 63. Middle East & Africa Gene Engineered Subunit Vaccine Sales Market Share by Type (2019-2024)
Figure 64. Middle East & Africa Gene Engineered Subunit Vaccine Sales Market Share by Application (2019-2024)
Figure 65. Egypt Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 66. South Africa Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 67. Israel Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 68. Turkey Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 69. GCC Country Gene Engineered Subunit Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Gene Engineered Subunit Vaccine in 2023
Figure 71. Manufacturing Process Analysis of Gene Engineered Subunit Vaccine
Figure 72. Industry Chain Structure of Gene Engineered Subunit Vaccine
Figure 73. Channels of Distribution
Figure 74. Global Gene Engineered Subunit Vaccine Sales Market Forecast by Region (2025-2030)
Figure 75. Global Gene Engineered Subunit Vaccine Revenue Market Share Forecast by Region (2025-2030)
Figure 76. Global Gene Engineered Subunit Vaccine Sales Market Share Forecast by Type (2025-2030)
Figure 77. Global Gene Engineered Subunit Vaccine Revenue Market Share Forecast by Type (2025-2030)
Figure 78. Global Gene Engineered Subunit Vaccine Sales Market Share Forecast by Application (2025-2030)
Figure 79. Global Gene Engineered Subunit Vaccine Revenue Market Share Forecast by Application (2025-2030)
